Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 2025年第二次临时股东会决议公告 | 2025-09-15 | Chinese | |
| 百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告 | 2025-09-11 | Chinese | |
| 百奥泰 自愿披露关于Qletli（阿达木单抗注射液）获得英国MHRA上市批准的公告 | 2025-09-10 | Chinese | |
| 百奥泰 2025年第二次临时股东会会议资料 | 2025-09-05 | Chinese | |
| 百奥泰 关于召开2025年半年度科创板创新药行业集体业绩说明会的公告 | 2025-09-05 | Chinese | |
| 百奥泰 关于召开2025年第二次临时股东会的通知 | 2025-08-29 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 39230671 | 百奥泰 2025年第二次临时股东会决议公告 | 2025-09-15 | Chinese | ||
| 39230665 | 百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告 | 2025-09-11 | Chinese | ||
| 39230660 | 百奥泰 自愿披露关于Qletli（阿达木单抗注射液）获得英国MHRA上市批准的公告 | 2025-09-10 | Chinese | ||
| 39230651 | 百奥泰 2025年第二次临时股东会会议资料 | 2025-09-05 | Chinese | ||
| 39230644 | 百奥泰 关于召开2025年半年度科创板创新药行业集体业绩说明会的公告 | 2025-09-05 | Chinese | ||
| 39230637 | 百奥泰 关于召开2025年第二次临时股东会的通知 | 2025-08-29 | Chinese | ||
| 39230630 | 百奥泰 关于使用部分闲置募集资金暂时补充流动资金的公告 | 2025-08-20 | Chinese | ||
| 39230625 | 百奥泰 关于Usymro（乌司奴单抗注射液）获得欧洲EMA上市批准的公告 | 2025-08-20 | Chinese | ||
| 39230621 | 百奥泰2025年半年度报告 | 2025-08-20 | Chinese | ||
| 39230601 | 百奥泰生物制药股份有限公司内部审计制度 | 2025-08-20 | Chinese | ||
| 39230593 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见 | 2025-08-20 | Chinese | ||
| 39230587 | 百奥泰 2025年半年度报告摘要 | 2025-08-20 | Chinese | ||
| 39230579 | 百奥泰 关于修订及制定部分公司治理制度的公告 | 2025-08-20 | Chinese | ||
| 39230569 | 百奥泰 关于变更注册地址、修订《公司章程》并办理工商变更登记的公告 | 2025-08-20 | Chinese | ||
| 39230561 | 百奥泰生物制药股份有限公司信息披露暂缓与豁免事务管理制度 | 2025-08-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.